How did Regeneron's collaboration revenue perform in 2024?

Regeneron's collaboration revenue showed strong performance in 2024, driven by significant growth in key product sales and partnerships. 1. **Sanofi Collaboration**: Regeneron's collaboration with Sanofi yielded $1.3 billion in revenue, reflecting a collaboration profitability reaching an all-time high. This highlights the successful partnership and the contribution of collaborative efforts to Regeneron's revenue growth. 2. **Bayer Collaboration**: Additionally, the collaboration with Bayer contributed $375 million, with $353 million recognized as net profits outside the US. This adds to the overall collaboration revenue, underscoring the value of cross-partner collaborations in generating substantial financial returns. 3. **Overall Collaboration Performance**: The collaboration revenue from both Sanofi and Bayer, totaling $1.65 billion, signifies a robust collaboration portfolio for Regeneron. This, coupled with strong net product sales of key products like DUPIXENT and EYLEA, demonstrates the effectiveness of Regeneron's collaborative strategies in driving revenue growth. In conclusion, Regeneron's collaboration revenue in 2024 was robust, with significant contributions from partnerships with Sanofi and Bayer. These collaborations not only enhanced Regeneron's revenue streams but also highlighted the power of strategic alliances in the pharmaceutical sector.